Isoprinosine 500mg 50 Tablets

Product Information

Počas tehotenstva adojčenia sa liek môže podávať, len ak lekár zváži, že prínos prevažuje nad potenciálnym rizikom.

HAIDUSHKA, I.; ZLATEV, S. ISOPRINOSINE IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS. The Lancet. 1987-07, roč. 330, čís. 8551, s. 153. Dostupné online [cit. 2021-04-02]. ISSN 0140-6736. DOI 10.1016/s0140-6736(87)92349-x. BERAN, Jiří; ŠALAPOVÁ, Eva; ŠPAJDEL, Marian. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC infectious diseases. 11 07, 2016, roč. 16, čís. 1, s. 648. PMID 27821093 CALTAGIRONE, C.; CARLESIMO, A. Methisoprinol in the treatment of multiple sclerosis. A pilot study. Acta Neurologica Scandinavica. 1986-10, roč. 74, čís. 4, s. 293–296. PMID 2433887. Dostupné online [cit. 2021-04-02]. ISSN 0001-6314. DOI 10.1111/j.1600-0404.1986.tb03517.x. PMID 2433887. Litzman J, Lokaj J, Krejčí M, Pešák S, Morgan G. Isoprinosine does not protect against frequent respiratory tract infections in childhood. Eur J Pediatr. 1999;158(1):32–7. a b c d e ISOPRINOSINE, 500MG TBL NOB 100, Státní ústav pro kontrolu léčiv. www.sukl.cz [online]. [cit. 2021-03-10]. Dostupné online.

Alte produse ale producatorului EWOPHARMA INTERNATIONAL

Nitazoxanide has been shown to inhibit SARS-CoV-2 in in-vitro studies [ 57, 71]. In an in-vivo study based on a mouse model, nitazoxanide was found to markedly lower plasma IL-6 levels [ 70]. In a clinical trial conducted by Gamino-Arroyo et al., nitazoxanide did not show any difference when compared to placebo in patients with influenza [ 72]. The same trial included 17 cases of coronavirus and did not show any effect of nitazoxanide on the outcome. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787. Akútne ochorenia: u ochorení s krátkym vývojom liečba obvykle trvá 5-14 dní. Liečba má pokračovať ešte 1 alebo 2 dni po ústupe symptómov, prípadne dlhšie, podľa rozhodnutia lekára. Proportions of patients reporting recurrences, recurrence frequency, and mean duration of lesions during breakthrough recurrences in each treatment group during a 6 month treatment period; time to first recurrence during treatment and follow-up after treatment cessation. Lopinavir is a protease inhibitor used commonly for the treatment of HIV 1 infection. Ritonavir is used for boosting the lopinavir levels as a combination in sub-therapeutic doses for its inhibitory action on CYP3A4. In HIV, LPV inhibits the protease enzyme (aspartic protease family), thereby preventing the cleavage of Gag-Pol protein precursors. This results in the formation of immature and non-infectious virions. It is postulated that LPV has similar action on SARS-CoV-1 by inhibiting the chymotrypsin-like protease.

Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–6. Kao J-C, HuangFu W-C, Tsai T-T, Ho M-R, Jhan M-K, Shen T-J, et al. The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR. Beasley DWC, editor. PLoS Negl Trop Dis. 2018;12(8):e0006715. citas vīrusu infekcijas, tādas kā infekciozā mononukleoze (infekcija, kuru izraisa Epšteina-Barra vīruss), infekcija, kuru izraisa citomegalovīruss;PAŘÍZKOVÁ, Ranata. Péče o hospitalizované pacienty s COVID-19 - Doporučený postup FN HK [online]. Fakultní nemocnice Hradec Králové, Verze 2 - 18.11.2020 [cit. 2021-03-10]. Dostupné online. Sliva J, Pantzartzi CN, Votava M. Inosine pranobex: a key player in the game against a wide range of viral infections and non-infectious diseases. Adv Ther. 2019;36(8):1878–905.